Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs Biphasic Insulin Aspart 30/70 in Type 2 Diabetes
NCT00184626Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2004
- Primary completion
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated Hemoglobin A1c at 26 weeks. Started Sep 2004; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00184626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184626.